About RxTA1: a plain-language Thymosin Alpha-1 reader

What this site is

RxTA1 is a plain-language column on Thymosin Alpha-1 (the thymic immune peptide, made as the synthetic drug thymalfasin) — a bright, readable pass through the peer-reviewed literature. We read the studies, pull out what they actually measured, and write it up so a curious non-scientist can follow it without losing the technical detail underneath. Every quantitative claim here is tied to a citation you can check on the references page.

We cover this compound the way a good column covers a beat: organized, sourced, and honest about what's strong and what's shaky. That means we lead with the null phase-3 sepsis result as readily as the encouraging COVID-19 signals, because an honest read reports both.

What this site is not

No clinic sits behind this column, and no clinician is on staff — so nothing here is medical advice. We make, sell, and distribute nothing; there is nothing to buy and no vendor link to find. The work is a plain reading of published science.

The "rx" in the name is a framing device — the angle this column takes on the literature, signaling that it covers the clinical and regulatory side of this peptide — not a claim that the site prescribes, dispenses, or supplies anything. It does none of those. No doctors, no pharmacists, no clinical team, no consultations.

How we handle accuracy

Thymosin Alpha-1 is one of the most-confused peptides out there, so we're deliberate about three things. First, we keep it distinct from the molecules it's mixed up with — thymosin beta-4 (TB-500), thymulin, thymopentin, thymalin, and its precursor prothymosin alpha — which we lay out on the mechanism of action page. Second, we treat it as the immune modulator it is, not as an anabolic or performance compound, because that's what the science says it is. Third, we report its US regulatory status plainly: it is not FDA-approved for marketing in the United States. We use only generic naming and we don't endorse any unapproved use.